Pravachol Exclusivity: Teva Wins By Winning– FDA Wins By Losing?
Executive Summary
A recent D.C. federal appeals court decision affirming Teva's exclusivity period for Pravachol generics opens the door for new standard-setting by FDA on what conditions trigger the start of 180-day exclusivity
You may also be interested in...
FDA Favors Narrow Interpretation Of Exclusivity Court Decision Triggers
FDA's narrow policy on court decision triggers for 180-day exclusivity could increase the value of the generic exclusivity incentive, the agency says
FDA Favors Narrow Interpretation Of Exclusivity Court Decision Triggers
FDA's narrow policy on court decision triggers for 180-day exclusivity could increase the value of the generic exclusivity incentive, the agency says
Bristol Feels Plavix And Pravachol Pain; Does Relief Lie In Conservative R&D?
As Bristol-Myers Squibb prepares to weather patent losses for its two top-selling products - Pravachol and Plavix - the firm is sticking by a conservative approach to research & development